ARTICLE | Management Tracks
Meeker expands role at Rhythm; plus Biogen, Kronos, Citryll, Akcea, ImmunoGen, Circle, Antares and more
July 22, 2020 1:07 AM UTC
David Meeker will become president and CEO of obesity company Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) while remaining chairman, a title he’s held since 2017. He succeeds CFO Hunter Smith, who was serving as president and CEO on an interim basis. Meeker was president and CEO of KSQ Therapeutics Inc., and previously served as EVP and head of the Genzyme unit of Sanofi (Euronext:SAN; NASDAQ:SNY).
Biogen Inc. (NASDAQ:BIIB) said Michael McDonnell will succeed Jeffrey Capello as EVP and CFO, effective Aug. 15. McDonnell held the same position at IQVia Holdings Inc. (NYSE:IQV)...